ABSTRACr Angiotensin-converting enzyme activity in sarcoidosis is regarded both as a diagnostic feature and as an index of disease activity. Increased activity of this enzyme is thought to parallel macrophage and epithelioid cell activity. Beta-2-microglobulin, a low-molecular-weight protein associated with the histocompatibility antigens, is thought to reflect activation of immunocompetent cells, particularly lymphocytes. In 132 patients with known sarcoidosis no close association was found to exist between the results of the two assays (r = 0.53). Angiotensin-converting enzyme activity was raised in 33% and J32-microglobulin concentrations in 63% of patients with sarcoidosis. When analysed prospectively, the results of the two assays showed no correlation in 29 patients over periods of up to 19 months. Stage, duration of disease, and corticosteroid treatment showed no significant effect on levels of either angiotensin-converting enzyme or f62-microglobulin. The disparity between indices of macrophage and lymphocyte activation requires further study in sarcoidosis.
Detection of activity in sarcoidosis by conventional criteria such as those based on chest radiography or physiological studies is difficult. Cytological analysis of bronchoalveolar lavage fluid may be more informative,' but is impractical for repetitive studies. There is a need for a simple test which would reflect the activity of immunocompetent cells concerned in the pulmonary immune effector response. In 1974 Lieberman reported increased activity of serum angiotensin-converting enzyme in 13 patients with sarcoidosis who were not receiving corticosteroids.2 He noted that raised levels fell towards normal with corticosteroid treatment, and confirmed these findings in a larger study. 3 Beta-2-microglobulin is a low-molecular-weight protein which seems to be associated with several membrane proteins. It is present in very low concentrations normally, in a wide variety of body fluids. Mornex4 reported increased concentrations in sarcoidosis-in all patients with the acute disease or in relapse and also in most patients with quiescent disease. In two of his patients raised concentrations of fi2-Microglobulin fell towards normal with increased corticosteroid dose.
The purpose of the present study was to study serum levels of angiotensin-converting enzyme and in patients receiving corticosteroids did not differ significantly from that in non-treated patients. This is not what might have been anticipated in view of extensive evidence that corticosteroids depress raised levels of angiotensin-converting enzyme in sarcoidosis.
Our data for f32-microglobulin show that in both acute (2 7 ± 0 2) and chronic (3 05 ± 0 12) disease the population means significantly exceed the control population mean (1I75 ± 0-l1). This elevation may be a marker of the known pulmonary lymphocyte activation in sarcoidosis. As with angiotensinconverting enzyme, serum f32-microglobulin concentrations did not vary significantly with duration of disease or with corticosteroid treatment. In view of macrophage and lymphocyte activation in sarcoidosis we expected that there would be a correlation between indices of activation of these two types of immunological effector cells. It is currently accepted that estimation of serum angiotensin-converting enzyme in sarcoidosis has an important supportive role in the diagnosis and assessment of the disease.7 It has been shown to be increased in some patients with sarcoidosis. Levels tend to be higher in acute, disseminated disease, especially when corticosteroid treatment has not been given-as many as 70% of these patients having raised levels.9 Nearly all reports suggest that high levels of angiotensin-converting enzyme fall towards normal with corticosteroid treatment. Lieberman suggested that a fall in angiotensin-converting enzyme activity in response to corticosteroid treatment was a good prognostic sign, and that serial estimations could be of value in titrating an appropriate maintenance dose. 3 Silverstein pointed out that angiotensin-converting enzyme activity in the lymph nodes of patients with sarcoidosis was almost always increased and was diagnostically significant. ') Immunofluorescence techniques have shown that the enzyme is present in most epithelioid and giant cells of sarcoid granulomas and it has been suggested that this is the site of synthesis.'0
In 1968 Bergg'ard and Bearn isolated fi2-microglobulin from the urine of patients with renal tubular disorders. " In view of its low molecular weight (11 800) 22 Our findings suggest thatfi2-microglobulin concentrations do not adequately reflect the activity of sarcoidosis and a more sensitive marker in the systemic circulation is required for appropriate study of this disease. 
